Related Experiment Video
Updated: Jun 25, 2025

09:10
siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
7.2K
Cholesterol Modulation Attenuates the AD-like Phenotype Induced by Herpes Simplex Virus Type 1 Infection
Blanca Salgado1,2, Beatriz Izquierdo1,3, Alba Zapata1
1Centro de Biologia Molecular Severo Ochoa (CBM), CSIC-UAM, Universidad Autonoma de Madrid, 28049 Madrid, Spain.
Biomolecules
|May 24, 2024
Summary
Herpes simplex virus type 1 (HSV-1) infection causes Alzheimer's disease (AD)-like changes by altering cholesterol levels. Modulating cholesterol with MβCD reversed these changes and inhibited viral infection.
Area of Science:
- Neuroscience
- Virology
- Cell Biology
Background:
- Cholesterol is vital for cell membrane function and implicated in neurodegenerative disorders like Alzheimer's disease (AD).
- Herpes simplex virus type 1 (HSV-1) infection has been shown to induce an AD-like phenotype in cellular models.
Purpose of the Study:
- To investigate the role of cholesterol in HSV-1-induced neurodegeneration.
- To determine how modulating cellular cholesterol levels affects HSV-1 infection and AD-like pathology.
Main Methods:
- Utilized neuroblastoma cell lines (SK-N-MC and N2a).
- Manipulated cellular cholesterol levels using methyl-beta-cyclodextrin (MβCD).
- Assessed HSV-1 infection stages, cholesterol accumulation, and AD-related markers (amyloid-beta and phosphorylated tau).
Main Results:
- HSV-1 infection led to intracellular cholesterol accumulation in endolysosomal/autophagic compartments.
- MβCD treatment reversed cholesterol accumulation and inhibited HSV-1 infection at multiple stages.
- MβCD alleviated AD-like features, including lysosomal dysfunction and accumulation of amyloid-beta and phosphorylated tau.
Conclusions:
- Cellular cholesterol homeostasis is critical for HSV-1 infection and the development of neurodegeneration.
- Targeting cholesterol metabolism may offer a therapeutic strategy for managing HSV-1-induced neurodegenerative conditions, including Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Role of Neurotransmitters in Memory
526
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
526

